2 Plummeting Pharma Stocks

ARLZ stock is on track for its worst session in almost 12 years

May 8, 2018 at 10:22 AM
facebook twitter linkedin

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) this morning reported a wider-than-expected first-quarter loss, withdrew its guidance, and said it was suspending all U.S. operations to shift sole focus to its Canadian business. The maker of Toprol-XL also warned it could run out of cash over the next 12 months. In reaction, ARLZ stock have plummeted 58.9% to trade at $0.63 -- fresh off a record low of $0.62, and on track for its worst day since June 2006.

The shares have now sliced through long-term support at $1.30, which had served as a floor since last October, and are staring at a 55% year-to-date deficit. This has put short sellers in a winning position, as well. While the stock is short-sale restricted (SSR) today, 3.3 million ARLZ shares are sold short -- 5% of Aralez Pharmaceuticals' available float.

Fellow pharma stock Nevro Corp (NYSE:NVRO) is also spiraling today, down 14.6% to trade at $78.77, after the chronic pain specialist reported a wider-than-forecast first-quarter loss on lower-than-expected revenue. Analysts have had mostly bearish reactions, too, with Wells Fargo and Northland Capital downgrading the shares to "market perform." And while Canaccord Genuity was one of three firms to lower its price target -- to $102 from $110 -- the brokerage said it could be time to buy the dip.

In fact, today's weakness runs counter to the stock's longer-term technical performance, with NVRO surging more than 45% from its December lows near $65 to yesterday's annual high of $94.34. Plus, today's bear gap is being contained near $76.10 -- a 61.8% Fibonacci retracement of this rally.

Short sellers, meanwhile, are likely cheering today's drastic drop. While the stock also landed on the SSR list, there are currently 3.67 million shares dedicated to these bearish bets -- a healthy 12.7% of Nevro's available float.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial


Special Offers from Schaeffer's Trading Partners